Variant Gene Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913529
rs121913529
0.100 GeneticVariation BEFREE Moreover, comparison of the survival of patients with tumors harboring G12V/A KRAS mutations with those harboring wild-type KRAS gene revealed that G12V/A KRAS mutations are prognostic biomarker for inferior PFS and OS in patients with mCRC treated with bevacizumab in univariate as well as multivariable analyses. 26662311

2017

dbSNP: rs121913529
rs121913529
0.100 GeneticVariation BEFREE In conclusion, KRAS G12V mutation is detectable in plasma of colorectal cancer patients by ddPCR and could be used as a non-invasive biomarker. 27043547

2016

dbSNP: rs121913529
rs121913529
0.100 GeneticVariation BEFREE Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. 25359494

2015

dbSNP: rs121913529
rs121913529
0.100 GeneticVariation BEFREE Our finding that KRAS codon 13 mutations (in particular G13D) are associated with inferior survival in BRAF wild-type CRCs in Chinese patients was not reported thus far. 25367198

2015

dbSNP: rs121913529
rs121913529
0.100 GeneticVariation BEFREE KRAS MASI is a significant event in colorectal cancer, specifically associated with G13D mutation, and featuring a heterogeneous spatial distribution, that may have a role to predict the response to EGFR inhibitors. 25609577

2015

dbSNP: rs121913529
rs121913529
0.100 GeneticVariation BEFREE In contrast, in KRAS-mutant CRC cells (DLD-1(G13D) and SW480(G12V)), KRAS knocked-down by KRAS-siRNA led to ERCC1 upregulation and increased oxaliplatin resistance. 23209813

2013

dbSNP: rs121913529
rs121913529
0.100 GeneticVariation BEFREE KRAS codon 12 mutations (in particular, c.35G>T), but not codon 13 mutations, are associated with inferior survival in BRAF wild-type colorectal cancer. 22753589

2013

dbSNP: rs121913529
rs121913529
0.100 GeneticVariation BEFREE KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. 23015072

2013

dbSNP: rs121913529
rs121913529
0.100 GeneticVariation BEFREE The aim of our study was to evaluate the combined effects of MSI, BRAF(V600E) and specific KRAS mutation (Gly → Asp; G12D, Gly → Asp, G13D; Gly → Val; G12V) on prognosis in 404 sporadic and 94 hereditary CRC patients. 20162668

2010

dbSNP: rs121913529
rs121913529
0.100 GeneticVariation BEFREE In this analysis, use of cetuximab was associated with longer overall and progression-free survival among patients with chemotherapy-refractory colorectal cancer with p.G13D-mutated tumors than with other KRAS-mutated tumors. 20978259

2010

dbSNP: rs121913529
rs121913529
0.100 GeneticVariation BEFREE We aimed to study proliferation and survival effects induced by BRAF inhibition in MSI CRC cell lines harbouring distinct genetic backgrounds (BRAF V600E or KRAS G13D). 18098337

2008

dbSNP: rs121913529
rs121913529
0.100 GeneticVariation BEFREE Furthermore, HNPCC CRCs had more G13D mutations than MSS (P < 0.0001), MSI-H (P = 0.02) or MSI-H tumours with hMLH1 hypermethylation (P = 0.03). 15294875

2005

dbSNP: rs121913529
rs121913529
0.100 GeneticVariation BEFREE Recent evidence associates the codon 12 valine-for-glycine (G12V) mutant Ki-Ras protein with higher stage and increased lethality of colorectal carcinomas, while the codon 12 aspartate-for-glycine (G12D) Ras mutation shows no such association. 10398103

1999

dbSNP: rs112445441
rs112445441
0.070 GeneticVariation BEFREE KRAS MASI is a significant event in colorectal cancer, specifically associated with G13D mutation, and featuring a heterogeneous spatial distribution, that may have a role to predict the response to EGFR inhibitors. 25609577

2015

dbSNP: rs112445441
rs112445441
0.070 GeneticVariation BEFREE Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. 25359494

2015

dbSNP: rs112445441
rs112445441
0.070 GeneticVariation BEFREE Our finding that KRAS codon 13 mutations (in particular G13D) are associated with inferior survival in BRAF wild-type CRCs in Chinese patients was not reported thus far. 25367198

2015

dbSNP: rs112445441
rs112445441
0.070 GeneticVariation BEFREE KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. 23015072

2013

dbSNP: rs112445441
rs112445441
0.070 GeneticVariation BEFREE In this analysis, use of cetuximab was associated with longer overall and progression-free survival among patients with chemotherapy-refractory colorectal cancer with p.G13D-mutated tumors than with other KRAS-mutated tumors. 20978259

2010

dbSNP: rs112445441
rs112445441
0.070 GeneticVariation BEFREE We aimed to study proliferation and survival effects induced by BRAF inhibition in MSI CRC cell lines harbouring distinct genetic backgrounds (BRAF V600E or KRAS G13D). 18098337

2008

dbSNP: rs112445441
rs112445441
0.070 GeneticVariation BEFREE Furthermore, HNPCC CRCs had more G13D mutations than MSS (P < 0.0001), MSI-H (P = 0.02) or MSI-H tumours with hMLH1 hypermethylation (P = 0.03). 15294875

2005

dbSNP: rs61764370
rs61764370
0.030 GeneticVariation BEFREE A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC. 26162609

2016

dbSNP: rs61764370
rs61764370
0.030 GeneticVariation BEFREE A PubMed search was conducted to identify all studies reporting on KRAS let-7 microRNA-binding site polymorphism (LCS6; rs61764370) and colorectal cancer outcome. 24890702

2015

dbSNP: rs61764370
rs61764370
0.030 GeneticVariation BEFREE Using site-specific homologous recombination, we inserted the rs61764370:T>G KRAS gene variant in the colorectal cancer cell line SW48 (SW48 +SNP) and assessed the cellular and biochemical phenotype. 24282149

2014

dbSNP: rs121913240
rs121913240
0.010 GeneticVariation BEFREE SP174, NRAS Q61R Mutant-Specific Antibody, Cross-Reacts With KRAS Q61R Mutant Protein in Colorectal Carcinoma. 28353383

2017

dbSNP: rs121913238
rs121913238
0.010 GeneticVariation BEFREE Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. 23400451

2014